ChemicalBook >> CAS DataBase List >>Apalutamide

Apalutamide

CAS No.
956104-40-8
Chemical Name:
Apalutamide
Synonyms
Apalutamide;4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide;4-(7-(6-cyano-5-(trifluoroMethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-MethylbenzaMide;ARN509, Apalutamide;Apalutamide (ARN-509);Copanlisib Dihydrochloride;Benzamide, 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-;4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide ARN-509;ARN;AR509
CBNumber:
CB92593622
Molecular Formula:
C21H15F4N5O2S
Molecular Weight:
477.43
MDL Number:
MFCD22380626
MOL File:
956104-40-8.mol
Last updated:2024-03-26 17:16:27

Apalutamide Properties

Density 1.59±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility ≥23.85 mg/mL in DMSO; insoluble in H2O; ≥7.33 mg/mL in EtOH
form solid
pka 13.83±0.46(Predicted)
FDA UNII 4T36H88UA7

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P280-P305+P351+P338
NFPA 704
0
2 0

Apalutamide price More Price(23)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 17132 ARN-509 ≥98% 956104-40-8 1mg $44 2024-03-01 Buy
Cayman Chemical 17132 ARN-509 ≥98% 956104-40-8 5mg $193 2024-03-01 Buy
Cayman Chemical 17132 ARN-509 ≥98% 956104-40-8 10mg $321 2024-03-01 Buy
TRC A726120 Apalutamide 956104-40-8 25mg $100 2021-12-16 Buy
ApexBio Technology A8364 ARN-509 956104-40-8 10mM(in 1mL DMSO) $105 2021-12-16 Buy
Product number Packaging Price Buy
17132 1mg $44 Buy
17132 5mg $193 Buy
17132 10mg $321 Buy
A726120 25mg $100 Buy
A8364 10mM(in 1mL DMSO) $105 Buy

Apalutamide Chemical Properties,Uses,Production

Description

ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate cancer treatment. Phase 3.

In vitro

ARN-509 (< 10 μM) inhibits androgen-mediated induction or repression of mRNA expression levels for 13 endogenous genes including PSA and TMPRSS2 in the LNCaP/AR prostate cancer cell line. ARN-509 (< 10 μM) inhibits the proliferative effect of R1881 (30 pM) in the LNCaP/AR prostate cancer cell line. ARN-509 (10 μM) impairs AR nuclear localization and thus reduces the concentration of AR available to bind androgen response elements (ARE) in LNCaP cells expressing AR-EYFP. ARN-509 (10 μM) is able to effectively compete with R1881 (1 nM) and prevent AR from binding to promoter regions. ARN-509 inhibits R1881-induced VP16-AR–mediated transcription with IC50 of 0.2 μM in Hep-G2 cells expressing a VP16-AR fusion protein and an ARE-driven luciferase reporter.

In vivo

ARN-509 (10 mg/kg/d, oral) inhibits tumor growth with decreased proliferative index and increased apoptotic rate in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dose dependently inhibits tumor growth with highest efficacy at dose of 30 mg/kg/day in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dosed at 10 mg/kg/d for 28 days results in a 3-fold reduction in prostates weight associated with lacking glandular secretory activity and 1.7-fold reduction in epididymis weight in adult male dogs. ARN-509 (10 mg/kg/d, oral) inhibits cell proliferation of prostate tissues in adult male dogs. ARN-509 is safe and well tolerated in 24 patients with metastatic CRPC who has progressed on prior treatments and peak plasma concentrations occurred 2 to 3 hours after administration. ARN-509 results in durable PSA declines at doses ranging from 30 to 300 mg in patients with metastatic CRPC. ARN-509 shows powerful anti-cancer activity and induces durable remissions long after therapy completion in castrate resistant prostate cancer mouse models.

Uses

Apalutamide is a second-generation antiandrogen used in the treatment of prostate cancer. It is a potent antagonist of androgen receptor with IC50 value of 16 nM. Binds androgen receptors, thereby inhibiting nuclear translocation, DNA binding and transcriptional activation. ARN-509 has therapeutic applications in non-metastatic, castration-resistant prostate cancer.

Pharmaceutical Applications

Apalutamide, also known as ARN-509, is used to treat certain types of castration-resistant prostate cancer or prostate cancer that has not spread to other parts of the body, but has not been helped by other medical treatments. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen to stop the growth and spread of cancer cells.
On September 17, 2019, the Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

Mechanism of action

Apalutamide, also known as ARN-509 and JNJ-56021927 , is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.

target

Androgen Receptor

Apalutamide Preparation Products And Raw materials

Global( 307)Suppliers
Supplier Tel Email Country ProdList Advantage
Beijing Mesochem Technology Co.,Ltd
+8613651027935 rachel@mesochem.com China 191 58
Changsha Junyu Chemexpress.co., Ltd
+86-13723890100 info@csjyyy.cn China 134 58
Jewim Pharmaceutical (Shandong) Co., Ltd.
+86-15552509998 +86-15621883869 liutf@jewim.com.cn China 251 58
Dorne Chemical Technology co. LTD
+86-13583358881 +86-18560316533 Ethan@dornechem.com China 294 58
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638 sales@sdperfect.com China 294 58
Hebei Xinsheng New Material Technology Co., LTD.
+86-16632316109 xinshengkeji@xsmaterial.com China 1100 58
Shandong Hanjiang Chemical Co., Ltd
+86-0533-2066820 +8618369939125 hanson@sdhanjiang.com China 1527 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 sales@capotchem.com China 29797 60
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21695 55

Related articles

  • What is Apalutamide
  • Apalutamide is a next-generation oral androgen receptor (AR) inhibitor that Janssen is developing for the treatment of prostat....
  • Dec 26,2023

Related Qustion

View Lastest Price from Apalutamide manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
ARN-509 pictures 2024-04-23 ARN-509
956104-40-8
US $1.00 / g 1g 99% 100kg Dorne Chemical Technology co. LTD
Apalutamide pictures 2024-04-22 Apalutamide
956104-40-8
US $0.00 / Kg/Bag 2Kg/Bag 0.99 20 tons Sinoway Industrial co., ltd.
Apalutamide pictures 2024-04-22 Apalutamide
956104-40-8
US $0.00 / Kg/Bag 2Kg/Bag 0.99 20 tons Sinoway Industrial co., ltd.
  • ARN-509 pictures
  • ARN-509
    956104-40-8
  • US $1.00 / g
  • 99%
  • Dorne Chemical Technology co. LTD
  • Apalutamide pictures
  • Apalutamide
    956104-40-8
  • US $0.00 / Kg/Bag
  • 0.99
  • Sinoway Industrial co., ltd.
  • Apalutamide pictures
  • Apalutamide
    956104-40-8
  • US $0.00 / Kg/Bag
  • 0.99
  • Sinoway Industrial co., ltd.

Apalutamide Spectrum

ARN-509 AR509 AR509 100G ARV-509 ARN-509;ARN 509; ARN509 4-(7-(4-Cyano-3-(trifluoromethyl)phenyl)-8-hydroxy-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-f AR509/AR-509 ARN ARN 509; ARN-509 CS-591 4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-N-methylbenzamide ARN-509 USP/EP/BP 4-(7-(6-cyano-5-(trifluoroMethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspirooctan-5-yl)-2-fluoro-N-MethylbenzaMide Benzamide, 4-[7-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl- 4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide ARN-509 4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide ARN509, Apalutamide Apalutamide (ARN-509) Copanlisib Dihydrochloride Apalumide Apalutamide JNJ-56021927 ARN-509 Apatamide Apalutamide JNJ 56021927 JNJ56021927 JNJ-56021927 956104-40-8 956140-40-8 C22H18F4N4O2S C21H15F4N5O2S Inhibitors LG API